Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma

Melanoma is the deadliest cutaneous cancer. Activating mutations in NRAS are found in 20% of melanomas. NRAS-mutant melanoma is more aggressive and, therefore, has poorer outcomes, compared to non-NRAS-mutant melanoma. Despite promising preclinical data, to date immune checkpoint inhibitors remain t...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Alvarez, Alejandro, Ortiz, Carolina, Muñoz-Couselo, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202735/
https://www.ncbi.nlm.nih.gov/pubmed/34135599
http://dx.doi.org/10.2147/OTT.S278095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202735/
https://www.ncbi.nlm.nih.gov/pubmed/34135599
http://dx.doi.org/10.2147/OTT.S278095

Ejemplares similares